Literature DB >> 33260129

Reconversion of neurosurgical practice in times of the SARS-CoV-2 pandemic: a narrative review of the literature and guideline implementation in a Mexican neurosurgical referral center.

Sergio Díaz-Bello1,2, Alan Hernández-Hernández1,2, Gerardo Y Guinto-Nishimura1,2, Michel G Mondragón-Soto1,2, Monica Lem-Carrillo1,2, Alberto González-Aguilar3,2, Juan M Calleja-Castillo3,2, Adolfo Leyva-Rendón2, Pablo León-Ortiz2, Carmen M Chávez-Piña2,4, Gustavo A Pando-Tarín2,4, Sonia I Mejía-Pérez2,5, Jesús Taboada-Barajas2,6, Elsa D Zavala-Álvarez2,7, José L Soto-Hernández2,7, Graciela Cárdenas2,7, Juan L Gómez-Amador1,2.   

Abstract

OBJECTIVE: The coronavirus disease 2019 (COVID-19) pandemic has forced the modification of surgical practice worldwide. Medical centers have been adapted to provide an efficient arrangement of their economic and human resources. Although neurosurgeons are not in the first line of management and treatment of COVID-19 patients, they take care of patients with neurological pathology and potential severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, the authors describe their institutional actions against the pandemic and compare these actions with those in peer-reviewed publications.
METHODS: The authors conducted a search using the MEDLINE, PubMed, and Google Scholar databases from the beginning of the pandemic until July 11, 2020, using the following terms: "Neurosurgery," "COVID-19/SARS-CoV-2," "reconversion/modification," "practice," "academy," and "teaching." Then, they created operational guidelines tailored for their institution to maximize resource efficiency and minimize risk for the healthcare personnel.
RESULTS: According to the reviewed literature, the authors defined the following three changes that have had the greatest impact in neurosurgical practice during the COVID-19 pandemic: 1) changes in clinical practices; 2) changes in the medical care setting, including modifications of perioperative care; and 3) changes in the academic teaching methodology.
CONCLUSIONS: The Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez" is one of the major referral centers for treating highly complex neurosurgical pathologies in Mexico. Its clinical and neurosurgical practices have been modified with the implementation of specific interventions against the spread of COVID-19. These practical and simple actions are remarkably relevant in the context of the pandemic and can be adopted and suited by other healthcare centers according to their available resources to better prepare for the next event.

Entities:  

Keywords:  COVID-19 pandemic; SARS-CoV-2; actions; modification/retraining; neurosurgery

Year:  2020        PMID: 33260129     DOI: 10.3171/2020.9.FOCUS20553

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  4 in total

1.  Challenges and Outcomes of COVID-19 Positive Neurosurgical Patients: An Institutional Experience With Emphasis on Modifications of Neurosurgical Practice.

Authors:  Binoy K Singh; Biswajit Dey; Deb K Boruah; Aishik Mukherjee; Sumit Kumar; Manoranjan Sharma; Pranjal Phukan
Journal:  Cureus       Date:  2021-12-09

2.  Grace Under Pressure: Resiliency of Quality Monitoring of Stroke Care During the Covid-19 Pandemic in Mexico City.

Authors:  Raul Medina-Rioja; Gina González-Calderón; Sergio Saldívar-Dávila; Alexander Estrada Saúl; Erika Gayón-Lombardo; Nicole Somerville-Briones; Juan Manuel Calleja-Castillo
Journal:  Front Neurol       Date:  2022-04-06       Impact factor: 4.086

3.  The effects of the coronavirus disease 2019 pandemic on neurospine surgery practice in the referral center hospital developing country.

Authors:  Galih Indra Permana; Muhammad Faris; Eko Agus Subagio; Abdul Hafid Bajamal
Journal:  Surg Neurol Int       Date:  2021-12-20

Review 4.  How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology?

Authors:  Angus Airth; James R Whittle; James Dimou
Journal:  J Clin Neurosci       Date:  2022-09-08       Impact factor: 2.116

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.